In Phase A, individuals will acquire distinct doses and schedules of oral ABBV-744 pill to determine Safe and sound dosing regimen. Added contributors will likely be enrolled within the identified monotherapy dosign program. In Phase B, participants will obtain oral ruxolitinib and ABBV-744 will be presented as "increase-on" therapy. In https://abbv-744forsmallcelllungc14680.pages10.com/detailed-notes-on-abbv-744-brd4-inhibitor-mechanism-of-action-67477722